Two 2024 approvals, ensifentrine and dupilumab, ended a decade of inhaler-only competition in the US COPD maintenance market.

Through 2023 the US COPD maintenance market was a two-horse inhaler race: GSK's Trelegy Ellipta and AstraZeneca's Breztri Aerosphere, both single-inhaler ICS/LAMA/LABA triples competing on exacerbation and mortality data (IMPACT and ETHOS). The strategic question was device, dosing, and formulary tier, not mechanism. That question is now obsolete for the patients who still exacerbate on triple therapy.

In mid-2024 the FDA approved ensifentrine (Ohtuvayre), the first novel inhaled mechanism in COPD in more than twenty years, and dupilumab (Dupixent), the first biologic ever approved in COPD. They do not compete head-to-head: ensifentrine is a non-steroidal add-on usable at any step, while dupilumab is gated to the roughly type-2/eosinophilic endotype on maximal triple therapy. The commercial contest is now about which failure phenotype a payer will pay to treat, and with what.

Two new mechanisms split the triple-therapy-failure population by endotype, not efficacy.

Five questions this report answers:

Q1 - Which patients convert to ensifentrine versus dupilumab, and how large is each addressable pool?

Q2 - Does dupilumab's biologic profile displace ensifentrine, or do they stack on the same exacerbator?

Q3 - How defensible are GSK's and AstraZeneca's incumbent triples once biology enters the conversation?

Q4 - What do the IMPACT and ETHOS trials show for Trelegy and Breztri's mortality claims?

Q5 - Where does roflumilast still hold a niche now that two new add-ons exist?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#COPD #US #CompetitiveIntelligence #AXLRx #PharmaMarketAccess

Live report page:  https://axlrx.ai/copd/competitive-intelligence/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-   hello@axlrx.ai

Web-   https://axlrx.ai/